Omega-3 and the Brain: What Research Shows About Protecting Cognition

The omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are not the same substance, even though they are often mentioned together. DHA is the dominant long-chain omega-3 in neuronal membranes and substantially affects their fluidity and signal conductance. EPA is primarily involved in anti-inflammatory cascades. The body synthesizes both from the plant precursor ALA, but the conversion is extremely inefficient: direct sources — fatty fish or supplements — are needed to adequately supply the brain.

Why does the brain need DHA?

Neuronal membranes are especially rich in DHA. This fatty acid determines the physical properties of the membrane — its fluidity, the speed of synaptic vesicle formation, and receptor efficiency. DHA deficiency is linked to impaired neurotransmission: receptors function less effectively and synaptic contacts form more slowly. Beyond its structural role, DHA and its metabolites (resolvins, protectins) limit neuroinflammation — chronic inflammation in the brain is considered one of the mechanisms of neurodegeneration.

Dietary DHA comes primarily from fatty marine fish. Supplements based on fish oil or algal oil provide a standardized dose independent of region and access to fresh fish.

What do randomized trials show?

Shahinfar et al. (Scientific Reports, 2025) conducted a systematic review and dose-response meta-analysis of 58 RCTs (database search through December 2024). For each additional 2,000 mg of omega-3 per day the authors report the following standardized effect sizes: global cognitive ability — SMD 1.08 (95% CI 0.73–1.44, GRADE low), attention — SMD 0.98 (95% CI 0.41–1.54, GRADE low), primary memory — SMD 0.87 (95% CI 0.17–1.56, GRADE moderate), visuospatial function — SMD 0.86 (95% CI 0.46–1.27, GRADE moderate).

A more conservative estimate came from a meta-analysis covering 26,881 participants aged 40 and older (Barros et al., Nutrients, 2025): the effect size for cognitive improvement on the MMSE was 0.16 (95% CI 0.01–0.32). The result is statistically significant but clinically modest. Seven of the nine included systematic reviews nevertheless confirmed improved outcomes in the intervention group.

Who benefits from omega-3 supplementation?

A systematic review of 10 RCTs (Deshmukh et al., Cureus, 2024) distinguishes between stages: in mild cognitive impairment (MCI), 2,000 mg DHA per day produced significant improvement in cognitive function and hippocampal volume. In moderate to severe Alzheimer's disease, 18 months of 2,000 mg DHA per day showed no benefit. In other words, the effect is recorded at early stages of decline, not once neurodegeneration is already pronounced.

A personalized approach is supported by Castellanos-Perilla et al. (Expert Review of Neurotherapy, 2024): carriers of the APOE4 allele show a blunted response to omega-3 supplements compared with non-carriers. Furthermore, women have baseline plasma DHA levels on average 15% higher than men on a comparable diet, which also influences individual response. Polymorphisms in the FADS1 and FADS2 genes, which govern the rate of ALA-to-EPA/DHA conversion, additionally explain the variation in outcomes between individuals.

What is the optimal dose?

Clinical studies have used doses ranging from 160 to 4,000 mg/day over periods of three to forty months. There is no clear linear effect: Shahinfar et al. (2025) identified nonlinear dose-response relationships for episodic memory and global cognition, implying an optimal range rather than a "more is better" principle. The majority of positive RCTs used 900–2,000 mg DHA+EPA per day.

What remains unclear?

The data are heterogeneous. One large observational study in the ADNI cohort (Liao et al., Journal of Prevention of Alzheimer's Disease, 2026) found that omega-3 supplement users showed a faster rate of decline on several scales. The authors themselves note that the result does not establish causality and that reverse confounding is possible (people with incipient decline are more likely to start taking supplements). This is an observational design without randomization, and it does not override the body of RCT evidence, but it is a reminder of the limitations.

Long-term (more than three years), well-designed RCTs accounting for genotype and baseline DHA status are needed. Until those exist, the available data support omega-3 supplementation as a complementary, but not standalone, tool for cognitive support.